ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatocellular carcinoma"

  • 2020 American Transplant Congress

    Post-Transplant Recurrence Following Yttrium-90 Treatment in Liver Transplant Recipients with Hepatocellular Carcinoma

    O. Rizzo, T. Kitajima, M. Kavousi, S. Yeddula, M. Rizzari, K. Collins, A. Yoshida, M. S. Abouljoud, S. Nagai

    Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI

    *Purpose: Yttrium-90 microspheres radioembolization (Y90) has shown to be effective as a bridging therapy for patients with advanced hepatocellular carcinoma (HCC) while on waiting list…
  • 2020 American Transplant Congress

    Potential Benefits of Y-90 Radiation Microspheres for Bridging Liver Candidates with Hepatocellular Carcinoma to Liver Transplant

    S. Pelletier1, J. Durden2, S. Shan2, P. Vargas3, N. Goldaracena1

    1University of Virginia Health System, Charlottesville, VA, 2School of Medicine, University of Virginia Health System, Charlottesville, VA, 3Department of Surgery, University of Virginia Health System, Charlottesville, VA

    *Purpose: In October 2015, the UNOS policy for hepatocellular carcinoma (HCC) exception scores was changed to modify the maximum exception value and prolong the time…
  • 2020 American Transplant Congress

    Imaging Features and Diagnostic Accuracy of MRI in Combined Hepatocholangiocarcinoma

    M. Najjar1, J. Makkar1, S. Sun1, J. Zou1, O. Perez1, P. Jiang1, Y. Saenger1, E. Zheng1, E. Verna1, A. Mathur1, A. Griesemer1, K. Halazun2, B. Samstein2, T. Kato1, J. Emond1

    1Columbia University Medical Center/New-York Presbyterian, New York, NY, 2Weill Cornell Medicine, New York, NY

    *Purpose: Combined hepatocholangiocarcinomas (HCC-CCA) are rare tumors with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) differentiations. They are usually associated with a worse prognosis after…
  • 2020 American Transplant Congress

    Adjuvant Immunotherapy for Liver Transplant Recipients with Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells

    M. Ohira1, R. Hotta1, Y. Imaoka1, K. Sato1, N. Tanimine1, H. Tahara1, K. Ide1, T. Kobayashi1, Y. Tanaka1, A. Tzakis2, S. Nishida2, H. Ohdan1

    1Hiroshima University, Hiroshima, Japan, 2University of Miami, Miami, FL

    *Purpose: Development of an effective adjuvant therapy to prevent HCC recurrence after liver transplantation (LT) is an important medical requirement. Immunosuppressive regimens currently used after…
  • 2020 American Transplant Congress

    Efficacy of Radiofrequency Ablation in the Treatment of Patients with Hepatocellular Carcinoma and Compensated Liver Disease: A Pathological Evaluation of Liver Explants

    W. Alhamoudi1, I. Salih2, S. Yousif2, M. Shawkat3, K. Bzeizi2, A. Albenmousa2, S. Alghamdi2, M. Sturdevant2, D. Broering2, H. Alsuhaibani2

    1Medicine, King Saud University, Riyadh, Saudi Arabia, 2Liver Transplant, King Faisal Specialist Hospital, Riyadh, Saudi Arabia, 3Internal Medicine, Minia University, Minia, Egypt

    *Purpose: Radiofrequency ablation (RFA) is a safe and effective treatment for patients with limited hepatocellular carcinoma (HCC). Ablative outcomes have been largely based on radiological…
  • 2020 American Transplant Congress

    Cirrhosis-Driven Immune Dysfunction is Associated with Poor Response to DEB-TACE and Waitlist Dropout in Hepatocellular Carcinoma Patients While Awaiting Liver Transplantation

    K. Nunez, T. Sandow, M. Hibino, A. Cohen, P. Thevenot

    Ochsner Health System, New Orleans, LA

    *Purpose: Hepatocellular carcinoma (HCC) recurrence after transplantation is associated with higher tumor grade on explant, failure to respond to DEB-TACE, and pretreatment lymphopenia. We prospectively…
  • 2020 American Transplant Congress

    Prognostic Impact of Peritumoral Neutrophil Infiltration on Hepatocellular Carcinoma Recurrence Following Liver Transplantation

    M. Najjar1, K. Halazun2, M. Mondal1, A. Srivastava1, M. Moore1, E. Rizk1, R. Gartrell1, H. Remotti1, L. Fazlollahi1, E. Verna1, A. Griesemer1, A. Mathur1, B. Samstein2, J. Emond1, Y. Saenger1

    1Columbia University Irving Medical Center, New York, NY, 2Weill Cornell Medicine, New York, NY

    *Purpose: Peritumoral neutrophil (PMN) infiltration has been associated with poor clinical outcomes in various tumors; however, its role in hepatocellular carcinoma (HCC) remains understudied. Moreover,…
  • 2019 American Transplant Congress

    DOME: A New Strategy for Prioritizing Hepatocellular Carcinoma Patients on the Liver Transplant Waitlist

    C. Rickert1, M. Akan2, Z. Leung3, J. F. Markmann1, S. Tayur2, H. Zhao3, H. Yeh1

    1Massachusetts General Hospital, Boston, MA, 2Tepper School of Business, Carnegie Mellon University, Pittsburgh, PA, 3City University of Hong Kong, Hong Kong, China

    *Purpose: Currently, adult HCC patients are prioritized for liver transplantation by receiving MELD exception points, determined primarily by time on waitlist without regard to actual…
  • 2019 American Transplant Congress

    Outcome Of Living Donor Liver Transplantation In Elderly Patients >65 Years With And Without Hepatocellular Carcinomas: A Retroepsective Analysis

    A. Thorat, L. Jeng, S. Hsu, H. Yang, C. Yeh, T. Chen, K. Poon, P. Li

    Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan

    *Purpose: The elderly patients > 65 years with end-stage liver disease that require liver transplantation has been steadily increased over last decade in Taiwan and…
  • 2019 American Transplant Congress

    Adjuvant Immunotherapeutic Approach For Liver Transplant Recipients With Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells

    M. Ohira1, R. Hotta1, Y. Imaoka1, K. Sato1, Y. Tanaka1, A. G. Tzakis2, S. Nishida3, H. Ohdan1

    1Hiroshima University, Hiroshima, Japan, 2Cleveland Clinic Florida, Weston, FL, 3New York Medical College, Valhalla, NY

    *Purpose: Although liver transplantation (LT) is a preferred treatment for selected patients with Hepatocellular carcinoma (HCC), HCC-recurrence would be a still important medical problem. Most…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 23
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences